Cancer Signal Triggers Vytorin Study Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Panel finds “no credible evidence” of increased cancer risk; SEAS trial misses its primary endpoint.
You may also be interested in...
New Look At Ezetimibe Fails To Confirm Vytorin Cancer Signal
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.
New Look At Ezetimibe Fails To Confirm Vytorin Cancer Signal
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.
States Subpoena Schering-Plough For Vytorin Documents
Several states are seeking information relating to the ENHANCE trial, Vytorin promotion and stock sales by company executives.